BRAF and colorectal carcinoma: To confirm the utility of this prognostic marker across all disease stages of CRC, we next stratified cMMR BRAF mutant patients by stages, and found that this survival advantage with the nuclear ERK/p38 score was potentiated in patients with stage III CRC.